126 related articles for article (PubMed ID: 11767306)
1. Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography.
Rivory LP; Clarke SJ; Boyer M; Bishop JF
J Chromatogr B Biomed Sci Appl; 2001 Dec; 765(2):135-40. PubMed ID: 11767306
[TBL] [Abstract][Full Text] [Related]
2. Column-switching high-performance liquid chromatographic method for the determination of a thymidylate synthase inhibitor, LY231514, an investigational agent for the treatment of solid tumors, in human plasma.
Hamilton CL; Kirkwood JA
J Chromatogr B Biomed Appl; 1994 Apr; 654(2):297-303. PubMed ID: 8044293
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.
Ouellet D; Periclou AP; Johnson RD; Woodworth JR; Lalonde RL
Cancer Chemother Pharmacol; 2000; 46(3):227-34. PubMed ID: 11021740
[TBL] [Abstract][Full Text] [Related]
4. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA
Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma.
Bobin-Dubigeon C; Amiand MB; Herrenknecht C; Bard JM
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(24):2451-6. PubMed ID: 19560408
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
8. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
Wang Y; Zhao R; Chattopadhyay S; Goldman ID
Cancer Res; 2002 Nov; 62(22):6434-7. PubMed ID: 12438230
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
Jones RJ; Twelves CJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
[TBL] [Abstract][Full Text] [Related]
12. Biochemical pharmacology of pemetrexed.
Calvert AH
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):13-7. PubMed ID: 15655931
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
Villela LR; Stanford BL; Shah SR
Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
15. Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection.
Synold TW; Xi B; Newman EM; Muggia FM; Doroshow JH
J Chromatogr B Biomed Appl; 1996 Aug; 683(2):245-9. PubMed ID: 8891922
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and disposition of the antifolate LY231514 in mice and dogs.
Woodland JM; Barnett CJ; Dorman DE; Gruber JM; Shih C; Spangle LA; Wilson TM; Ehlhardt WJ
Drug Metab Dispos; 1997 Jun; 25(6):693-700. PubMed ID: 9193870
[TBL] [Abstract][Full Text] [Related]
17. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
[TBL] [Abstract][Full Text] [Related]
18. Distribution of the novel antifolate pemetrexed to the brain.
Dai H; Chen Y; Elmquist WF
J Pharmacol Exp Ther; 2005 Oct; 315(1):222-9. PubMed ID: 15987831
[TBL] [Abstract][Full Text] [Related]
19. Determination of O6-benzylguanine in human plasma by reversed-phase high-performance liquid chromatography.
Stefan TL; Ingalls ST; Gerson SL; Willson JK; Hoppel CL
J Chromatogr B Biomed Appl; 1996 Jun; 681(2):331-8. PubMed ID: 8811444
[TBL] [Abstract][Full Text] [Related]
20. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
Li L; Agarwal S; Elmquist WF
Drug Metab Dispos; 2013 Mar; 41(3):659-67. PubMed ID: 23297298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
